Skip to content
Home / Media Hub / News and Press / Building the Operating Model for a €2 Billion CDMO: How CordenPharma is Scaling Global Growth

Building the Operating Model for a €2 Billion CDMO: How CordenPharma is Scaling Global Growth, by Dr. Michael Quirmbach

PharmaNetwork No 70 & 71, October 2026

News
30 Sep 26
Dr. Michael Quirmbach, Board Member & Senior Advisor, CordenPharma
by Dr. Michael Quirmbach
Board Member & Senior Advisor, CordenPharma
Over the past 12 years, I have had the opportunity to help guide CordenPharma through a remarkable transformation. We have evolved from a diversified specialty manufacturer into a leading global CDMO for complex modalities, with a strong focus on peptides, injectables, lipids & Lipid Nanoparticles (LNPs), and small molecules (both normal and highly potent compounds). This evolution has been shaped by changing customer expectations for integrated solutions, deeper scientific expertise, global supply security, faster development timelines, and true strategic partnerships. By remaining focused on these needs, we have positioned CordenPharma as a trusted partner to both leading pharmaceutical companies and emerging biotech innovators.


Customer Segments with the Highest Growth Potential

Over the past 12 years, I have seen the relationship between pharmaceutical companies and their CDMO partners change significantly. Reliable manufacturing remains essential, but customers now expect much more. They want scientific expertise, integrated capabilities, global reach, and partners that can support increasingly complex products from development through commercialization.

This shift is particularly visible among large pharmaceutical companies and leading biotechnology businesses developing GLP-1 and next-generation metabolic therapies. Rapid growth in this market has created exceptional demand for large-scale peptide manufacturing, while available industry capacity continues to fall short. Securing the right capacity has therefore become a strategic consideration that can directly affect development plans, launch readiness, and continuity of commercial supply.

Meeting this demand requires more than installing additional equipment. Customers need experienced teams, robust processes, reliable scale-up, and quality systems capable of supporting demanding global programs. They also need partners prepared to invest with a long-term view. We recognized the potential of peptides years ago and made a deliberate decision to invest ahead of demand. That commitment remains central to our strategy.

Emerging biotechnology innovators represent another important growth segment. Many are advancing promising peptide, RNA, and injectable programs with focused internal resources. They are not simply looking to outsource a manufacturing step. They need partners that can contribute scientific insight, regulatory support, technical problem-solving, and a clear path from clinical development to commercial scale.
In my experience, this collaboration creates the greatest value when it begins early. Decisions taken during development can have lasting implications for process robustness, scalability, quality, cost, and regulatory readiness. Addressing these considerations from the outset can help avoid unnecessary transfers or redevelopment later.

Supply chain resilience has also become a much greater priority. Customers increasingly seek dual-sourcing strategies, regional manufacturing options, and greater flexibility across their supply networks. Our expanding presence in the United States, Europe, and Asia responds directly to this need. A global network creates real value when it operates through aligned quality standards and coordinated processes, providing regional options without requiring customers to manage the connections among individual sites.

Read our White Paper: Choosing the Right Sterile Injectable Manufacturing CDMO

Technologies that Strengthen Complex Modalities

Peptides represent CordenPharma’s largest growth engine and are expected to account for the majority of our future expansion. The success of GLP-1 medicines has demonstrated their potential in diabetes, obesity, and metabolic disease, while the broader peptide pipeline continues to expand across additional indications.

We have built our position through sustained investment in technology, people, and manufacturing capacity. The next phase of growth, however, cannot be supported by capacity alone. It will require increasingly sophisticated approaches to synthesis, purification, analytics, process control, scale-up, and Drug Product development.

Advanced peptide technologies such as TAPS, flow SPPS, continuous chromatography, process analytical technology, and alternative purification methods can improve efficiency, process understanding, scalability, and sustainability. As molecules become more complex and programs advance toward larger commercial volumes, these technologies will become increasingly important.

Oral peptide development also presents an important opportunity. Injectable delivery will remain essential for many peptide therapies, but oral administration could improve convenience and broaden access for suitable products. Progress requires the close integration of peptide expertise with formulation development, Oral Solid Dosage capabilities, analytical science, and scalable manufacturing.

Lipids and lipid nanoparticles are another important area. Their role in enabling RNA and mRNA medicines is well established, while pipelines in gene-based and other advanced medicines continue to develop. Our experience in custom Lipids and integrated LNP manufacturing gives us a strong foundation from which to support this market. By connecting lipid development, formulation, analytics, process development, and manufacturing, we can provide a more efficient pathway toward clinical and commercial supply.

Highly Potent APIs and associated Drug Product manufacturing also offer considerable growth potential as targeted oncology therapies and precision medicines advance. These products require specialized containment, technical expertise, and tightly controlled manufacturing environments. Our Highly Potent API and Oral Solid Dosage capabilities allow us to connect Drug Substance and Drug Product activities, reducing transfers and creating clearer accountability.

Learn about CordenPharma Nanomedicines

End-to-End Service Offerings are Key to Organic Growth

Today, many pharmaceutical and biotechnology companies want partners capable of taking a broader view of the product lifecycle. They seek coordinated development and manufacturing services, access to scientific specialists, and a defined path from early development through commercial supply. This is why integrated end-to-end solutions are central to our strategy.

Our peptide offering illustrates this approach. We are creating a connected pathway from development through commercial peptide API manufacturing and onward to injectable or oral Drug Product supply. Differentiation does not come simply from placing several services within one company. It comes from ensuring that the responsible teams work together around a common product strategy.

Early coordination allows Drug Product requirements to inform Drug Substance development. Analytical strategies can be aligned, formulation challenges considered, and commercial-scale requirements anticipated. This reduces transfer risk, creates greater continuity, and gives the customer a clearer line of accountability. For us, integration means organizing expertise around the product rather than expecting customers to navigate boundaries among technologies, functions, or sites.

Sterile injectable manufacturing is another area with significant growth potential. The expansion of biologics, peptides, and other complex therapeutics is increasing demand for sophisticated aseptic fill-finish capabilities. Customers require manufacturing assets as well as the technical and quality expertise needed to manage sensitive molecules, challenging formulations, scale changes, and progression from clinical to commercial supply.

Our investments in Injectables are closely connected to our Peptides strategy. Combining peptide API manufacturing with injectable Drug Product supply can reduce transfers, simplify supply chains, and support more efficient decisions as a products advance toward commercialization.

The strongest service offering is therefore not defined by one asset. It is defined by how effectively development, scale-up, Drug Substance, Drug Product, analytics, regulatory support, and commercial manufacturing are connected. That integration creates a more efficient customer experience and a more reliable pathway to patients.

 

Read the full PharmaNetwork Article here

Want to find out more?

Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.